Skip to content
Publications
2025
- Osteoarthritis increases the risk of inflammatory arthritis due to immune checkpoint inhibitors associated with tissue-resident memory T cells.
Paiola M, Portnoy DM, Hao LY, Bukhari S, Winchester RJ, Henick BS, Mor A, Gartshteyn Y. J Immunother Cancer. 2025 Mar 21;13(3):e010758. doi: 10.1136/jitc-2024-010758. PMID: 40118498
- Surviving Grade 4 ICANS: A Case Report and Discussion of Emerging Management Strategies.
Jonokuchi AJ, Yu AW, Kaur G, Satwani P, Reshef R, Wesley SF. J Child Neurol. 2025 Sep;40(8):691-695. doi: 10.1177/08830738251335055. Epub 2025 May 15. PMID: 40370190.
- Electroencephalography in patients with immune effector cell-associated neurotoxicity syndrome (ICANS).
Wesley SF, Friedman AR, Gordillo C, Kent PF, Reshef R. J Neurol Sci. 2025 Jul 24;476:123632. doi: 10.1016/j.jns.2025.123632. PMID: 40743599.
2024
- Inhibition of IL-25/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity.
Hu X, Bukhari SM, Tymm C, Adam K, Lerrer S, Henick BS, Winchester RJ, Mor A. J Immunother Cancer. 2024 Mar 21;12(3):e008482. doi: 10.1136/jitc-2023-008482. PMID: 38519059
- Novel Risk Factors for Predicting Immune-effector Cell Associated Neurotoxicity Syndrome (ICANS) (P3-14.001)
Friedman AR, Tozlu C, Gordilla C, Reshef R, Wesley SF. Neurology. 2024 Apr 9;102 (17_suppl_1).
- Safety of CAR T-Cell Therapy in Active Autoimmune Diseases: A Case Report (P3-14.003).
Friedman A, Lipsky A, Gordillo C, Reshef R, Wesley SF. Neurology. 2024 Apr 9;102 (17_suppl_1).
2023
2022
- Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors.
Bukhari S, Henick BS, Winchester RJ, Lerrer S, Adam K, Gartshteyn Y, Maniar R, Lin Z, Khodadadi-Jamayran A, Tsirigos A, Salvatore MM, Lagos GG, Reiner SL, Dallos MC, Mathew M, Rizvi NA, Mor A. Cell Rep Med. 2023 Jan 17;4(1):100868. doi: 10.1016/j.xcrm.2022.100868. Epub 2022 Dec 12. PMID: 36513074
- Axicabtagene Ciloleucel in Patients Ineligible for ZUMA-1 Because of CNS Involvement and/or HIV: A Multicenter Experience.
Yuen CA, Hsu JM, Van Besien K, Reshef R, Iwamoto FM, Haggiagi A, Liechty B, Zhang C, Wesley SF*, Magge R*. J Immunother. 2022 Jun 1;45(5):254-262. doi: 10.1097/CJI.0000000000000416. Epub 2022 Apr 11. PMID: 35404315. *co-senior authors
2021
- Neurological Immunotoxicity from Cancer Treatment.
Wesley SF, Haggiagi A, Thakur KT, De Jager PL. Int J Mol Sci. 2021 Jun 23;22(13):6716. doi: 10.3390/ijms22136716. PMID: 34201529; PMCID: PMC8268562.
- Intracranial Complications From Immune Checkpoint Therapy in a Patient With NSCLC and Multiple Sclerosis: Case Report.
Lu BY, Isitan C, Mahajan A, Chiang V, Huttner A, Mitzner JR, Wesley SF, Goldberg SB. JTO Clin Res Rep. 2021 May 18;2(6):100183. doi: 10.1016/j.jtocrr.2021.100183. PMID: 34590030; PMCID: PMC8474265.
- Neurotoxicity Related to CAR T-Cell Therapy in Patients with Secondary Central Nervous System Lymphoma.
Yuen C, Wesley SF, Van Besien K, Hsu JM, Reshef R, Iwamoto F, Haggiagi A, Magge R. NCMP-02. Neuro Oncol. 2021 Nov 12;23(Suppl 6):vi147.
- A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).
Dumbrava EE, Dougan ML, Gupta S, Cappelli L, Katsumoto TR, Rahma OE, Painter J, Wang Y, Suarez-Almazor ME, Reid P, Wesley SF, Hafler DA, Bingham CO, Warner BM, Chung L, Ott PA, Kluger H, Khosroshahi A, Tawbi HA, Sharon E. J of Clin Oncol, 2021 39:15_suppl, TPS2676-TPS2676.
2020
- Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1 Programmed Death-Ligand 1 Blockade in SCLC.
Ricciuti B, Naqash AR, Naidoo J, Sehgal K, Miller A, Kehl K, Venkatraman D, Sands J, Lamberti G, Recondo G, Zhang J, Macherla S, Baig S, Walker P, Rangachari D, Gainor JF, Costa DB, Rizvi N, Sholl LM, Nishino M, Henick B, Farago AF, Awad MM. JTO Clin Res Rep. 2020 Jul 15;1(4):100074. doi: 10.1016/j.jtocrr.2020.100074. eCollection 2020 Nov. PMID: 34589955
Back to top
